Profiling of cross-functional peptidases regulated circulating peptides in BRCA1 mutant breast cancer

Jia Fan, Muy Kheng M. Tea, Chuan Yang, Li Ma, Qing H. Meng, Ye Hu, Christian F. Singer, Mauro Ferrari

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Women with inherited BRCA1 mutations are more likely to develop breast cancer (BC); however, not every carrier will progress to BC. The aim of this study was to identify and characterize circulating peptides that correlate with BC patients carrying BRCA1 mutations. Circulating peptides were enriched using our well-designed nanoporous silica thin films (NanoTraps) and profiled by mass spectrometry to identify among four clinical groups. To determine the corresponding proteolytic processes and their sites of activity, purified candidate peptidases and synthesized substrates were assayed to verify the processes predicted by the MERPOS database. Proteolytic processes were validated using patient serum samples. The peptides, KNG1K438-R457 and C 3fS1304-R1320, were identified as putative peptide candidates to differentiate BRCA1 mutant BC from sporadic BC and cancer-free BRCA1 mutant carriers. Kallikrein-2 (KLK2) is the major peptidase that cleaves KNG1K438-R457 from kininogen-1, and its expressions and activities were also found to be dependent on BRCA1 status. We further determined that KNG1K438-R457 is cleaved at its C-terminal arginine by carboxypeptidase N1 (CPN1). Increased KLK2 activity, with decreased CPN1 activity, results in the accumulation of KNG1K438-R457 in BRCA1-associated BC. Our work outlined a useful strategy for determining the peptide-petidase relationship and thus establishing a biological mechanism for changes in the peptidome in BRCA1-associated BC.

Original languageEnglish (US)
Pages (from-to)1534-1545
Number of pages12
JournalJournal of Proteome Research
Volume15
Issue number5
DOIs
StatePublished - May 6 2016
Externally publishedYes

Fingerprint

Peptide Hydrolases
Breast Neoplasms
Peptides
Tissue Kallikreins
Carboxypeptidase B2
Kininogens
Carboxypeptidases
Silicon Dioxide
Mass spectrometry
Mutation
Thin films
Substrates
Mass Spectrometry
Databases
Serum
Neoplasms

Keywords

  • BRCA1 mutation
  • breast cancer
  • circulating peptides biomarker
  • kallikrein-2
  • Kininogen-1

ASJC Scopus subject areas

  • Biochemistry
  • Chemistry(all)

Cite this

Profiling of cross-functional peptidases regulated circulating peptides in BRCA1 mutant breast cancer. / Fan, Jia; Tea, Muy Kheng M.; Yang, Chuan; Ma, Li; Meng, Qing H.; Hu, Ye; Singer, Christian F.; Ferrari, Mauro.

In: Journal of Proteome Research, Vol. 15, No. 5, 06.05.2016, p. 1534-1545.

Research output: Contribution to journalArticle

Fan, Jia ; Tea, Muy Kheng M. ; Yang, Chuan ; Ma, Li ; Meng, Qing H. ; Hu, Ye ; Singer, Christian F. ; Ferrari, Mauro. / Profiling of cross-functional peptidases regulated circulating peptides in BRCA1 mutant breast cancer. In: Journal of Proteome Research. 2016 ; Vol. 15, No. 5. pp. 1534-1545.
@article{092256c2f0524ef8997cd0b2ba1df528,
title = "Profiling of cross-functional peptidases regulated circulating peptides in BRCA1 mutant breast cancer",
abstract = "Women with inherited BRCA1 mutations are more likely to develop breast cancer (BC); however, not every carrier will progress to BC. The aim of this study was to identify and characterize circulating peptides that correlate with BC patients carrying BRCA1 mutations. Circulating peptides were enriched using our well-designed nanoporous silica thin films (NanoTraps) and profiled by mass spectrometry to identify among four clinical groups. To determine the corresponding proteolytic processes and their sites of activity, purified candidate peptidases and synthesized substrates were assayed to verify the processes predicted by the MERPOS database. Proteolytic processes were validated using patient serum samples. The peptides, KNG1K438-R457 and C 3fS1304-R1320, were identified as putative peptide candidates to differentiate BRCA1 mutant BC from sporadic BC and cancer-free BRCA1 mutant carriers. Kallikrein-2 (KLK2) is the major peptidase that cleaves KNG1K438-R457 from kininogen-1, and its expressions and activities were also found to be dependent on BRCA1 status. We further determined that KNG1K438-R457 is cleaved at its C-terminal arginine by carboxypeptidase N1 (CPN1). Increased KLK2 activity, with decreased CPN1 activity, results in the accumulation of KNG1K438-R457 in BRCA1-associated BC. Our work outlined a useful strategy for determining the peptide-petidase relationship and thus establishing a biological mechanism for changes in the peptidome in BRCA1-associated BC.",
keywords = "BRCA1 mutation, breast cancer, circulating peptides biomarker, kallikrein-2, Kininogen-1",
author = "Jia Fan and Tea, {Muy Kheng M.} and Chuan Yang and Li Ma and Meng, {Qing H.} and Ye Hu and Singer, {Christian F.} and Mauro Ferrari",
year = "2016",
month = "5",
day = "6",
doi = "10.1021/acs.jproteome.6b00010",
language = "English (US)",
volume = "15",
pages = "1534--1545",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - Profiling of cross-functional peptidases regulated circulating peptides in BRCA1 mutant breast cancer

AU - Fan, Jia

AU - Tea, Muy Kheng M.

AU - Yang, Chuan

AU - Ma, Li

AU - Meng, Qing H.

AU - Hu, Ye

AU - Singer, Christian F.

AU - Ferrari, Mauro

PY - 2016/5/6

Y1 - 2016/5/6

N2 - Women with inherited BRCA1 mutations are more likely to develop breast cancer (BC); however, not every carrier will progress to BC. The aim of this study was to identify and characterize circulating peptides that correlate with BC patients carrying BRCA1 mutations. Circulating peptides were enriched using our well-designed nanoporous silica thin films (NanoTraps) and profiled by mass spectrometry to identify among four clinical groups. To determine the corresponding proteolytic processes and their sites of activity, purified candidate peptidases and synthesized substrates were assayed to verify the processes predicted by the MERPOS database. Proteolytic processes were validated using patient serum samples. The peptides, KNG1K438-R457 and C 3fS1304-R1320, were identified as putative peptide candidates to differentiate BRCA1 mutant BC from sporadic BC and cancer-free BRCA1 mutant carriers. Kallikrein-2 (KLK2) is the major peptidase that cleaves KNG1K438-R457 from kininogen-1, and its expressions and activities were also found to be dependent on BRCA1 status. We further determined that KNG1K438-R457 is cleaved at its C-terminal arginine by carboxypeptidase N1 (CPN1). Increased KLK2 activity, with decreased CPN1 activity, results in the accumulation of KNG1K438-R457 in BRCA1-associated BC. Our work outlined a useful strategy for determining the peptide-petidase relationship and thus establishing a biological mechanism for changes in the peptidome in BRCA1-associated BC.

AB - Women with inherited BRCA1 mutations are more likely to develop breast cancer (BC); however, not every carrier will progress to BC. The aim of this study was to identify and characterize circulating peptides that correlate with BC patients carrying BRCA1 mutations. Circulating peptides were enriched using our well-designed nanoporous silica thin films (NanoTraps) and profiled by mass spectrometry to identify among four clinical groups. To determine the corresponding proteolytic processes and their sites of activity, purified candidate peptidases and synthesized substrates were assayed to verify the processes predicted by the MERPOS database. Proteolytic processes were validated using patient serum samples. The peptides, KNG1K438-R457 and C 3fS1304-R1320, were identified as putative peptide candidates to differentiate BRCA1 mutant BC from sporadic BC and cancer-free BRCA1 mutant carriers. Kallikrein-2 (KLK2) is the major peptidase that cleaves KNG1K438-R457 from kininogen-1, and its expressions and activities were also found to be dependent on BRCA1 status. We further determined that KNG1K438-R457 is cleaved at its C-terminal arginine by carboxypeptidase N1 (CPN1). Increased KLK2 activity, with decreased CPN1 activity, results in the accumulation of KNG1K438-R457 in BRCA1-associated BC. Our work outlined a useful strategy for determining the peptide-petidase relationship and thus establishing a biological mechanism for changes in the peptidome in BRCA1-associated BC.

KW - BRCA1 mutation

KW - breast cancer

KW - circulating peptides biomarker

KW - kallikrein-2

KW - Kininogen-1

UR - http://www.scopus.com/inward/record.url?scp=84969244649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969244649&partnerID=8YFLogxK

U2 - 10.1021/acs.jproteome.6b00010

DO - 10.1021/acs.jproteome.6b00010

M3 - Article

VL - 15

SP - 1534

EP - 1545

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 5

ER -